RAFAEL
RUBIO GARCÍA
Profesor titular de universidad
![Foto de RAFAEL](/img/uploaded/6CA654DD031F6FEF08160B3A8AA5CC20.jpg)
![Foto de Hospital Universitari de Bellvitge](/img/noimage_org.png)
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitari de Bellvitge (28)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
2023
-
Post-mortem findings in Spanish patients with COVID-19; a special focus on superinfections
Frontiers in Medicine, Vol. 10
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018
BMC infectious diseases, Vol. 22, Núm. 1, pp. 379
2019
-
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202
2018
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
2017
2016
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study
American Journal of Transplantation, Vol. 16, Núm. 2, pp. 679-687
-
MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression
PLoS ONE, Vol. 11, Núm. 5
-
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, but Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial
Medicine (United States), Vol. 95, Núm. 6
2015
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792
2014
-
Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2014)
Enfermedades Infecciosas y Microbiologia Clinica Monografias, Vol. 32, Núm. 7, pp. 446e1-446e42
-
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 7, pp. 447-458
-
Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries
AIDS, Vol. 28, Núm. 16, pp. 2461-2473
2009
-
(Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))
Enfermedades Infecciosas y Microbiologia Clinica
-
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks
Journal of Acquired Immune Deficiency Syndromes, Vol. 50, Núm. 5, pp. 474-481
-
Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality
Current HIV Research, Vol. 7, Núm. 2, pp. 224-230
-
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201